UK markets closed

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.54+0.07 (+1.08%)
As of 12:15PM EST. Market open.

Alector, Inc.

131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States
415 231 5660
https://www.alector.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees246

Key executives

NameTitlePayExercisedYear born
Dr. Arnon Rosenthal Ph.D.Co-Founder, CEO & Director1.02MN/A1956
Dr. Sara Kenkare-Mitra Ph.D.President and Head of Research & Development1.19MN/A1968
Dr. Marc Grasso M.D.CFO, Principal Financial Officer & Principal Accounting Officer738.05kN/A1973
Dr. Gary Romano M.D., Ph.D.Chief Medical Officer602.98kN/A1962
Mr. Peter Heutink Ph.D.Chief Scientific OfficerN/AN/AN/A
Katie HoganSenior Director of Corporate Communication & Investor RelationsN/AN/AN/A
Ms. Danielle Pasqualone J.D., Ph.D.General CounselN/AN/AN/A
Ms. Clare Hunt M.B.A.Chief People OfficerN/AN/AN/A
Ms. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance OfficerN/AN/AN/A
Ms. Virginia DeJesus-Rueff M.B.A.Chief of Staff & Head of StrategyN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Corporate governance

Alector, Inc.’s ISS governance QualityScore as of 1 February 2024 is 7. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.